China Healthy Aging Cohort Study (China-Ageing)

June 23, 2024 updated by: Xuanwu Hospital, Beijing
This is a community-based prospective cohort study in China. The study has been initialized in 2024 and included older residents. The goal of this observational study is to explore the risk factors related to disability and dementia in the elderly Chinese community population, and develop a risk prediction model for disability and dementia.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

This is a community-based prospective cohort study in China. Individuals who were aged 60 years or older, had lived in the communities for more than 1 year, and had signed the informed consent form were enrolled in the present study. The study has been initiated in 2024 and aimed to explore the risk factors related to disability and dementia in the elderly Chinese population, and develop a risk prediction model for disability and dementia. This work consists of three steps as follows. First, by integrating the data of the elderly cohort of 4 communities in Beijing, Shenzhen, Haikou and Hangzhou, we plan to establish a Chinese elderly database. Second, to explore the risk factors of disability and dementia in elderly Chinese. Third, to construct risk prediction models of disability and dementia in Chinese elderly.

Study Type

Observational

Enrollment (Estimated)

6780

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Beijing, China, 100053
        • Recruiting
        • Xuanwu Hospital, Capital Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Community residents aged 60 years or older in China

Description

Inclusion Criteria:

  • Aged 60 years or older
  • Lived in the community for more than 1 year
  • Signed the informed consent form

Exclusion Criteria:

  • Cannot complete the survey

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Total
All subjects
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prevalence and incidence of functional disability using a population-based survey
Time Frame: An average of 1 to 2 years
Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder(Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.
An average of 1 to 2 years
The prevalence and incidence of mild cognitive impairment using a population-based survey
Time Frame: An average of 1 to 2 years
Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.
An average of 1 to 2 years
The prevalence and incidence of dementia using a population-based survey
Time Frame: An average of 1 to 2 years
Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.
An average of 1 to 2 years
The conversion rate of normal to mild cognitive impairment
Time Frame: An average of 1 to 2 years
Percentage of enrolled population that convert from normal to mild cognitive impairment
An average of 1 to 2 years
The conversion rate of mild cognitive impairment to dementia
Time Frame: An average of 1 to 2 years
Percentage of enrolled population that convert from mild cognitive impairment to dementia
An average of 1 to 2 years
The prevalence and incidence of movement disorder using a population-based survey
Time Frame: An average of 1 to 2 years
Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.
An average of 1 to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yi Tang, MD., PhD, Xuanwu Hospital, Beijing

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 13, 2024

Primary Completion (Estimated)

June 1, 2063

Study Completion (Estimated)

June 1, 2063

Study Registration Dates

First Submitted

June 17, 2024

First Submitted That Met QC Criteria

June 23, 2024

First Posted (Actual)

June 25, 2024

Study Record Updates

Last Update Posted (Actual)

June 25, 2024

Last Update Submitted That Met QC Criteria

June 23, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Death

Clinical Trials on No intervention

Subscribe